2 Citations (Scopus)

Abstract

The treatment of patients with high-dose chemotherapy and autologous transplantation for recurrent or high-risk lymphomas has greatly expanded over the past few years. With the use of new supportive care measures such as newer antibiotics and hematopoietic growth factors, the morbidity and mortality rate associated with this therapy have diminished. This in turn has allowed successful use of the therapy earlier in the disease course, with resultant increases in disease-free survival rates. Future trials will strive to utilize new therapies and supportive care measures to improve on the results even further.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalAnnual Review of Medicine
Volume44
DOIs
StatePublished - Jan 1 1993

Fingerprint

Bone Marrow Transplantation
Hodgkin Disease
Bone
Chemotherapy
Intercellular Signaling Peptides and Proteins
Anti-Bacterial Agents
Autologous Transplantation
Therapeutics
Disease-Free Survival
Lymphoma
Survival Rate
Morbidity
Drug Therapy
Mortality

Keywords

  • chemotherapy
  • hematopoietic growth factors
  • non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bone marrow transplantation for Hodgkin's disease and lymphoma. / Vose, Julie Marie; Armitage, James Olen.

In: Annual Review of Medicine, Vol. 44, 01.01.1993, p. 255-263.

Research output: Contribution to journalReview article

@article{83b726723aab4efd89d4ca21d27ab44c,
title = "Bone marrow transplantation for Hodgkin's disease and lymphoma",
abstract = "The treatment of patients with high-dose chemotherapy and autologous transplantation for recurrent or high-risk lymphomas has greatly expanded over the past few years. With the use of new supportive care measures such as newer antibiotics and hematopoietic growth factors, the morbidity and mortality rate associated with this therapy have diminished. This in turn has allowed successful use of the therapy earlier in the disease course, with resultant increases in disease-free survival rates. Future trials will strive to utilize new therapies and supportive care measures to improve on the results even further.",
keywords = "chemotherapy, hematopoietic growth factors, non-Hodgkin's lymphoma",
author = "Vose, {Julie Marie} and Armitage, {James Olen}",
year = "1993",
month = "1",
day = "1",
doi = "10.1146/annurev.me.44.020193.001351",
language = "English (US)",
volume = "44",
pages = "255--263",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Bone marrow transplantation for Hodgkin's disease and lymphoma

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The treatment of patients with high-dose chemotherapy and autologous transplantation for recurrent or high-risk lymphomas has greatly expanded over the past few years. With the use of new supportive care measures such as newer antibiotics and hematopoietic growth factors, the morbidity and mortality rate associated with this therapy have diminished. This in turn has allowed successful use of the therapy earlier in the disease course, with resultant increases in disease-free survival rates. Future trials will strive to utilize new therapies and supportive care measures to improve on the results even further.

AB - The treatment of patients with high-dose chemotherapy and autologous transplantation for recurrent or high-risk lymphomas has greatly expanded over the past few years. With the use of new supportive care measures such as newer antibiotics and hematopoietic growth factors, the morbidity and mortality rate associated with this therapy have diminished. This in turn has allowed successful use of the therapy earlier in the disease course, with resultant increases in disease-free survival rates. Future trials will strive to utilize new therapies and supportive care measures to improve on the results even further.

KW - chemotherapy

KW - hematopoietic growth factors

KW - non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0027412163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027412163&partnerID=8YFLogxK

U2 - 10.1146/annurev.me.44.020193.001351

DO - 10.1146/annurev.me.44.020193.001351

M3 - Review article

C2 - 8476247

AN - SCOPUS:0027412163

VL - 44

SP - 255

EP - 263

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -